Market Place
Sourcing Support
Inmune Bio Reveals 2025 Results And Business Update
30 Mar 2026 //
GLOBENEWSWIRE
Inmune Bio Showcases Mindful Trial At AD/PD 2026 Plenary
19 Mar 2026 //
GLOBENEWSWIRE
Inmune Bio Unveils Xpro1595 Plan In Alzheimer`s Webinar
23 Feb 2026 //
GLOBENEWSWIRE
INmune to Host Webinar on CORDStrom Data
19 Feb 2026 //
GLOBENEWSWIRE
INmune Bio Secures FDA Alignment for XPro1595 in Early AD
12 Feb 2026 //
GLOBENEWSWIRE
INmune Bio Reviews 2025 Milestones, Plans 2026 Initiatives
27 Jan 2026 //
GLOBENEWSWIRE
Peer Study Highlights Therapeutic Potential of CORDStrom Platform
05 Dec 2025 //
GLOBENEWSWIRE
Inmune Bio Presents Phase 2 Imaging Data At CTAD Conference
01 Dec 2025 //
GLOBENEWSWIRE
Inmune Bio Reveals Q3 2025 Results and Business Update
30 Oct 2025 //
GLOBENEWSWIRE
Inmune Bio Submits Phase 2 Mindful Trial Results In Alzheimer
29 Sep 2025 //
GLOBENEWSWIRE
INmune Bio Completes First CORDStrom Run at CGT Catapult
15 Sep 2025 //
GLOBENEWSWIRE
INmune Bio Unveils Q2 2025 Results, Updates Business
07 Aug 2025 //
GLOBENEWSWIRE
INmune Bio`s in Kmune™ Trial in Prostate Cancer Meets Endpoints
04 Aug 2025 //
GLOBENEWSWIRE
INmune Bio Reveals MINDFuL Trial Findings on XPro™ at Conference
29 Jul 2025 //
GLOBENEWSWIRE
INmune Bio`s Alzheimer`s Drug Falls Short of Mid-Stage Study Goal
01 Jul 2025 //
REUTERS
INmune Bio Reports Key Findings from Phase 2 Trial of XPro™ in Al
30 Jun 2025 //
GLOBENEWSWIRE
INmune Bio, Inc. Closes $19M Offering Under Nasdaq Rules
30 Jun 2025 //
GLOBENEWSWIRE
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain
10 Jun 2025 //
GLOBENEWSWIRE
INmune Bio to Attend 2025 RBC Capital Markets Conference
14 May 2025 //
GLOBENEWSWIRE
INmune Bio Reports Q1 2025 Results and Business Update
08 May 2025 //
GLOBENEWSWIRE
INmune Bio to Report Q1 2025 Financial Results on May 8th
05 May 2025 //
GLOBENEWSWIRE
INmune Bio gets positive patent opinion for Cordstrom™ tech
16 Apr 2025 //
GLOBENEWSWIRE
INmune Bio partners with Cell and Gene Therapy Catapult
14 Apr 2025 //
GLOBENEWSWIRE
INmune Bio Announces 2024 Results and Business Update
27 Mar 2025 //
GLOBENEWSWIRE
INmune Opens Ph 2 High Dose Cohort In Trial For Prostate Cancer
12 Feb 2025 //
GLOBENEWSWIRE
INmune Bio Expands INKmune Trial in Prostate Cancer to Veterans
28 Jan 2025 //
GLOBENEWSWIRE
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
10 Dec 2024 //
GLOBENEWSWIRE
OmniScience & INmune Bio Partner for Ph 2 Alzheimer’s Trial
04 Dec 2024 //
GLOBENEWSWIRE
INmune Bio Completes Enrollment in Phase 2 Early Alzheimer`s Trial
13 Nov 2024 //
GLOBENEWSWIRE
INmune Bio Inc. Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
INmune Bio to Host Webinar on Cognitive Testing Methods
28 Oct 2024 //
#N/A
INmune Bio Inc. Publishes XPro™ Study In Cell Reports
24 Oct 2024 //
GLOBENEWSWIRE
INmune Bio to Participate in the Maxim Healthcare Virtual Summit
11 Oct 2024 //
GLOBENEWSWIRE
INmune Bio Reports Alzheimer`s Trial Interim Analysis
17 Sep 2024 //
GLOBENEWSWIRE
INmune Bio Announces $13.0 Million Registered Direct Offering
13 Sep 2024 //
GLOBENEWSWIRE
INmune Bio Initiates 2nd Cohort of INKmune™ in mCRPC Study
29 Apr 2024 //
GLOBENEWSWIRE
INmune Bio to Participate in Bairds Biotech Discovery Series Webcast
06 Feb 2024 //
GLOBENEWSWIRE
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune
02 Jan 2024 //
GLOBENEWSWIRE
INmune Shows that INB03 Enhances Uptake of Trastuzumab in HER2+ Breast Cancer
29 Nov 2023 //
GLOBENEWSWIRE
INmune Bio Patent Claims Covering INB16 Cell Line and INKmune Composition
31 Oct 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune
08 May 2023 //
GLOBENEWSWIRE
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimerâ Disease
19 Apr 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. Announces Submission of IND Application for INKmune to FDA
03 Apr 2023 //
GLOBENEWSWIRE
